Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
Hosted on MSN3mon
Oral SERD Impresses in Advanced Breast Cancer With ESR1 MutationsSAN ANTONIO -- Among patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, treatment with imlunestrant did not significantly improve progression-free survival (PFS ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine resistance before disease progression in HR-positive, HER2-negative advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback